Contents

Search


amoxicillin/vonoprazan

Indications: - treatment of Helicobacter pylori infection (FDA approved May 2022) Adverse effects: - dysgeusia, diarrhea, abdominal pain, headache, nasopharyngitis, hypertension, vulvovaginal candidiasis - Stevens-Johnson syndrome & toxic epidermal necrolysis - C difficile-associated diarrhea Notes: - available Fall 2022

General

pharmacologic combination

References

  1. Hamza Z Two New Regimens Win FDA Approval for H. Pylori Infection. Dual and triple vonoprazan-based treatments offer physicians another set of options. MedPage Today May 4, 2022 https://www.medpagetoday.com/gastroenterology/generalgastroenterology/98547
  2. Rokkas T, Ekmektzoglou K, Niv Y, et al. Comparative Efficacy and Safety of Potassium-Competitive Acid Blocker-Based Dual, Triple, and Quadruple Regimens for First-Line Helicobacter pylori Infection Treatment: A Systematic Review and Network Meta-Analysis. Am J Gastroenterol. 2024 Sep 19 PMID: 39298553 https://journals.lww.com/ajg/abstract/9900/comparative_efficacy_and_safety_of.1334.aspx

Components

amoxicillin (Amoxil, Polymox, Larotid, Trimox, DisperMox, Moxatag, A-cillin) vonoprazan (Voquezna)